Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Stock Report

| More

Nidlegy™ Phase III PIVOTAL trial meets the study's primary objective

Posted On: 2023-10-17 07:14:20 (Time Zone: IST)

Philogen S.p.A. (BIT:PHIL) and Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) are pleased to announce positive results from the Phase III PIVOTAL trial in patients with locally advanced fully resectable melanoma (NCT02938299). The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm). Patients were allowed to receive approved adjuvant systemic therapies after surgery in both arms.

According to the protocol, the primary endpoint of the study was the Recurrence-Free Survival (RFS) assessed per Blinded Independent Central Review (BICR) for patients treated with Nidlegy™, compared to the control arm. At median follow-up of 27.6 months in both groups, the study met its primary endpoint with a statistically significant and clinically meaningful improvement in RFS of the treatment arm compared to the control arm. This positive outcome was consistently in line with the Investigators' Assessment: a significant reduction of the hazard risk ratio of 33% (HR = 0.67) and 37% (HR = 0.63), respectively, favoring the treatment arm, was observed both in the BICR and in the Investigators' Assessment analysis.

Treatment-related adverse events observed with Nidlegy™ were benign and manageable, consistent with the proposed mechanism of action and with the favorable safety profile previously reported in the Phase II study [Danielli et al. (2015) Cancer Immunol. Immunother., 64, 999]. Grade 3 adverse events occurred in 24.8% of the treated patients. Neither grade 4 toxicity nor treatment-related deaths were observed in the study. Nidlegy™ treatment was not associated with the induction of autoimmune conditions.

PIVOTAL enrolled 257 patients in Europe across 22 clinical centers in Germany, Italy, France and Poland. The results, including sub-group analyses, will be presented at a forthcoming medical meeting.

Nidlegy™ is also being developed in dedicated Phase II clinical trials for the treatment of aggressive forms of non-melanoma skin cancer, including high-risk locally advanced basal cell carcinoma and cutaneous squamous cell carcinoma.

Prof. Dario Neri, co-founder, CEO and CSO of Philogen, commented: "We are extremely pleased to announce positive topline data emerging from our PIVOTAL program in locally advanced resectable melanoma. The clinical data in melanoma and high-risk non melanoma skin cancers bode well for the possible adoption of intralesional Nidlegy™ in a series of Dermato-Oncology indications. Philogen is currently executing six additional advanced clinical trials with registration potential featuring either Nidlegy™ or Fibromun, the company's most advanced product candidates, as active ingredients."

Alfredo Covelli, MD, Chief Medical Officer of Philogen, commented: "Neoadjuvant cytokine therapy for the treatment of locally advanced skin cancers enables a robust expansion of tumorinfiltrating lymphocytes. By anchoring interleukin-2 and tumor necrosis factor within the tumor mass through the L19 antibody moiety, we minimize systemic side effects while mounting a systemic robust anti-cancer immune response. This Phase 3 study merged the intralesional approach with IL2, pioneered by Prof. Claus Garbe more than 20 years ago, with the concepts of antibody-based tumor targeting, and with neoadjuvant therapy in locally advanced melanoma. The approach may find a broad applicability in different types of cancer."

Hellen De Kloet, Business Head - Western Europe and ANZ, Sun Pharma, said: "We are looking forward to commercializing Nidlegy™ in Europe, Australia and New Zealand as the first neoadjuvant immunotherapy for patients with resectable advanced melanoma. Nidlegy™, as an intralesional therapeutic option, addresses the existing significant unmet need for effective and well-tolerated treatments in patients, before undergoing surgery".

Philogen and Sun Pharma announced on May 30th, 2023, to have entered into distribution, license and supply agreement for commercializing Nidlegy™ in Europe, Australia and New Zealand for the treatment of skin cancers.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1134.90 as compared to the previous close of Rs. 1145.60. The total number of shares traded during the day was 28229 in over 1751 trades.

The stock hit an intraday high of Rs. 1147.25 and intraday low of 1134.00. The net turnover during the day was Rs. 32198570.00.

Click here to send ur comments or to

Other Headlines:

MOIL Ltd announces price revision from Dec 1, 2023

Dixon Technologies' subsidiary Padget Electronics inaugurates New Manufacturing Plant in Noida

ITD Cementation India Ltd secures new order worth ~Rs 1,001 Crore

Wardwizard Innovations & Mobility Ltd and Triton EV forge strategic partnership for Electric Vehicle Manufacturing

SPIC shuts down plants for maintenance

YES SECURITIES elevates Mr. Anshul Arzare as MD&CEO and Mr. Amar Ambani as Executive Director

BLS International Opens a New State-of-the-art Visa Application Centre in Delhi

IDFC FIRST Private Banking and Hurun India release India's Top 200 Self-made Entrepreneurs of the Millennia 2023

Cipla partners with TEACH to create career opportunities for hearing-impaired youth

Mehai Technology Ltd wins orders from West Bengal Government

Himadri Speciality Chemical Ltd acquires Himadri Clean Energy Ltd

Kesoram Industries Ltd to demerge cement division into UltraTech Cement Ltd

IIFL Finance Raises JPY 7.5 billion from Mizuho Bank

Wipro Unveils 'Lab of the Future' with AWS to Transform Lab Processes

DAC accorded AONs for procurement of LCH & LCA Mk 1A and for upgradation of Su-30 MKI Aircraft

Beekay Niryat Ltd's associate company to expand capacity of Extra Neutral Alcohol

Cantabil Retail India Ltd opens 6 new showrooms in November 2023

LTIMindtree Partners with Metasphere to Deliver Smart Sewers Solutions

Sonata Software Ltd fixes Dec 12, 2023 as record date for 1:1 bonus issue

Kanoria Energy and Infrastructure Ltd approves investment of Rs. 300 crore

Primo Chemicals Ltd commences commercial production of Caustic Soda Flakes

Max Life's e-commerce channel achieves 55% YoY+ growth in H1 FY24

IndiaMART Wins Prestigious Gold Award from LACP for Second Consecutive Year

Delta Corp Ltd expands into the Real Estate sector

Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe

Infosys and Shell Collaborate on Immersion Cooling Services to Enable Sustainability-First Data Centers

MRF Ltd enters into captive power purchase agreement with First Energy 5 Pvt Ltd

Nitin Spinners Ltd commences commercial production in Ring Spinning Unit

Datamatics introduces TruCap+ Marketplace, speeding up the time-to-automation for Intelligent Document Processing by up to 70%

Crompton wins the prestigious 23rd Greentech Environment Award 2023 for its environmental commitment

Peninsula Land Limited's strong performance paves way for equity capital raise & joint venture

Tata Coffee Ltd announces capacity expansion in Vietnam

Shriram AMC Allots Equity Shares on Conversion of Securities for Mission1

SJVN Synchronizes Second Unit of Naitwar Mori HEP with National Grid

The Derma Co released its first purpose film on Young Scientists inviting people to join the mission

Uno Minda launches the new range of LED Blinkers in the Indian Aftermarket

Federal Bank announces strategic collaboration with NeML for Enhanced eProcurement and eAuction Integration

BW Confidence Enterprise Pvt Ltd and Ganesh Benzoplast Ltd to develop LPG Onshore Import Terminal at JNPT

Eugia Pharma receives USFDA Approval for Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampule

SHREEJI enhances its presence with opening of new branch in Indore

Tata Tele Business Services Collaborates with Truecaller to offer 'Verified Business Caller ID Solution'

Integra Essentia Ltd receives order worth Rs. 120 million

Genesys International establishes Executive Innovation Board to propel India's First Comprehensive Map Stack

Best Airlines Rep selects 'AirGain to Provide Accurate Pricing Intelligence for Its Partner Airlines'

Confidence Petroleum India Ltd to raise Rs. 250 crores through preferential issue

DreamFolks strengthens its global presence through partnership with Grey Wall - one of Russia's leading lounge operator

Modi Naturals receives an order worth Rs ~230 crores from various OMCs for its ethanol division

Archit Organosys Ltd to form NOVEL AND NANO XTREME SOLUTIONS LLP for new business

PCBL Ltd to form JV with Kinaltek Pty Ltd

BW LPG's Significant Investment in Confidence Petroleum India Limited

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020